vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and KILROY REALTY CORP (KRC). Click either name above to swap in a different company.
KILROY REALTY CORP is the larger business by last-quarter revenue ($272.2M vs $168.4M, roughly 1.6× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -5.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -1.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Kilroy Realty Corp is a leading U.S. real estate investment trust that develops, owns, and operates premium office, life science, and mixed-use properties primarily across high-growth West Coast markets including Los Angeles, San Francisco, Seattle, and San Diego. It serves tenants across the technology, life sciences, media, and creative sectors, with a core focus on delivering sustainable, future-ready workspaces tailored to modern business needs.
ESPR vs KRC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $272.2M |
| Net Profit | — | $17.1M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 6.3% |
| Revenue YoY | 143.7% | -5.0% |
| Net Profit YoY | — | -73.7% |
| EPS (diluted) | $0.32 | $0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $272.2M | ||
| Q3 25 | $87.3M | $279.7M | ||
| Q2 25 | $82.4M | $289.9M | ||
| Q1 25 | $65.0M | $270.8M | ||
| Q4 24 | $69.1M | $286.4M | ||
| Q3 24 | $51.6M | $289.9M | ||
| Q2 24 | $73.8M | $280.7M | ||
| Q1 24 | $137.7M | $278.6M |
| Q4 25 | — | $17.1M | ||
| Q3 25 | $-31.3M | $162.3M | ||
| Q2 25 | $-12.7M | $79.6M | ||
| Q1 25 | $-40.5M | $43.7M | ||
| Q4 24 | — | $65.0M | ||
| Q3 24 | $-29.5M | $57.7M | ||
| Q2 24 | $-61.9M | $54.5M | ||
| Q1 24 | $61.0M | $55.7M |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | — | ||
| Q2 25 | 8.6% | — | ||
| Q1 25 | -34.0% | — | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | — | ||
| Q2 24 | 3.5% | — | ||
| Q1 24 | 52.5% | — |
| Q4 25 | — | 6.3% | ||
| Q3 25 | -35.9% | 58.0% | ||
| Q2 25 | -15.4% | 27.4% | ||
| Q1 25 | -62.2% | 16.1% | ||
| Q4 24 | — | 22.7% | ||
| Q3 24 | -57.2% | 19.9% | ||
| Q2 24 | -83.9% | 19.4% | ||
| Q1 24 | 44.3% | 20.0% |
| Q4 25 | $0.32 | $0.11 | ||
| Q3 25 | $-0.16 | $1.31 | ||
| Q2 25 | $-0.06 | $0.57 | ||
| Q1 25 | $-0.21 | $0.33 | ||
| Q4 24 | $-0.14 | $0.50 | ||
| Q3 24 | $-0.15 | $0.44 | ||
| Q2 24 | $-0.33 | $0.41 | ||
| Q1 24 | $0.34 | $0.42 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $179.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $5.4B |
| Total Assets | $465.9M | $10.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $179.3M | ||
| Q3 25 | $92.4M | $372.4M | ||
| Q2 25 | $86.1M | $193.1M | ||
| Q1 25 | $114.6M | $146.7M | ||
| Q4 24 | $144.8M | $165.7M | ||
| Q3 24 | $144.7M | $625.4M | ||
| Q2 24 | $189.3M | $835.9M | ||
| Q1 24 | $226.6M | $855.0M |
| Q4 25 | $-302.0M | $5.4B | ||
| Q3 25 | $-451.4M | $5.5B | ||
| Q2 25 | $-433.5M | $5.4B | ||
| Q1 25 | $-426.2M | $5.4B | ||
| Q4 24 | $-388.7M | $5.4B | ||
| Q3 24 | $-370.2M | $5.4B | ||
| Q2 24 | $-344.2M | $5.4B | ||
| Q1 24 | $-294.3M | $5.4B |
| Q4 25 | $465.9M | $10.9B | ||
| Q3 25 | $364.0M | $11.0B | ||
| Q2 25 | $347.1M | $10.9B | ||
| Q1 25 | $324.0M | $10.9B | ||
| Q4 24 | $343.8M | $10.9B | ||
| Q3 24 | $314.1M | $11.4B | ||
| Q2 24 | $352.3M | $11.5B | ||
| Q1 24 | $373.1M | $11.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $566.3M |
| Free Cash FlowOCF − Capex | — | $450.3M |
| FCF MarginFCF / Revenue | — | 165.4% |
| Capex IntensityCapex / Revenue | 0.0% | 42.6% |
| Cash ConversionOCF / Net Profit | — | 33.10× |
| TTM Free Cash FlowTrailing 4 quarters | — | $833.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $566.3M | ||
| Q3 25 | $-4.3M | $176.6M | ||
| Q2 25 | $-31.4M | $143.7M | ||
| Q1 25 | $-22.6M | $136.9M | ||
| Q4 24 | $-35.0M | $541.1M | ||
| Q3 24 | $-35.3M | $176.3M | ||
| Q2 24 | $-7.2M | $88.7M | ||
| Q1 24 | $53.8M | $167.9M |
| Q4 25 | — | $450.3M | ||
| Q3 25 | — | $148.7M | ||
| Q2 25 | — | $118.4M | ||
| Q1 25 | — | $115.6M | ||
| Q4 24 | — | $440.8M | ||
| Q3 24 | $-35.5M | $147.2M | ||
| Q2 24 | $-7.3M | $69.5M | ||
| Q1 24 | $53.8M | $151.9M |
| Q4 25 | — | 165.4% | ||
| Q3 25 | — | 53.1% | ||
| Q2 25 | — | 40.9% | ||
| Q1 25 | — | 42.7% | ||
| Q4 24 | — | 153.9% | ||
| Q3 24 | -68.7% | 50.8% | ||
| Q2 24 | -9.9% | 24.7% | ||
| Q1 24 | 39.0% | 54.5% |
| Q4 25 | 0.0% | 42.6% | ||
| Q3 25 | 0.0% | 10.0% | ||
| Q2 25 | 0.0% | 8.7% | ||
| Q1 25 | 0.0% | 7.9% | ||
| Q4 24 | 0.0% | 35.0% | ||
| Q3 24 | 0.3% | 10.1% | ||
| Q2 24 | 0.1% | 6.8% | ||
| Q1 24 | 0.1% | 5.7% |
| Q4 25 | — | 33.10× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 1.81× | ||
| Q1 25 | — | 3.13× | ||
| Q4 24 | — | 8.32× | ||
| Q3 24 | — | 3.06× | ||
| Q2 24 | — | 1.63× | ||
| Q1 24 | 0.88× | 3.01× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
KRC
Segment breakdown not available.
